State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Key Laboratory of Organ Failure Research (Ministry of Education), Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
Department of Pharmacy, Rational Medication Evaluation and Drug Delivery Technology Lab, Guangdong Key Laboratory of New Drug Screening, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
Clin Nutr. 2020 Aug;39(8):2517-2524. doi: 10.1016/j.clnu.2019.11.011. Epub 2019 Nov 15.
BACKGROUND & AIMS: Betaine (a micronutrient) has important biological functions (e.g., preventing premature apoptosis and serving as a methyl donor). We investigated the association between baseline serum betaine and the incident risk of first stroke in hypertensive patients.
We conducted a nested case-control study, including 622 patients with first stroke (including 502 ischemic stroke, 118 hemorrhagic stroke and 2 uncertain type of stroke) and 622 matched controls from the China Stroke Primary Prevention Trial (CSPPT). The study was conducted from May 2008 to August 2013. The study outcomes included first stroke and its subtypes: first ischemic and hemorrhagic stroke.
There was a U-shaped association between baseline serum betaine and the risk of first ischemic stroke. The risk of first ischemic stroke decreased with the increment of betaine (per 10 μmol/L increase: OR, 0.87; 95%CI: 0.77-0.99) in patients with betaine <77.7 μmol/L, while the risk of first ischemic stroke increased with the betaine increment (OR, 1.17; 95%CI: 1.01-1.36) in patients with betaine ≥77.7 μmol/L. However, there was no significant association between serum betaine and risk of first hemorrhagic stroke (per 10 μmol/L increase: OR, 0.98; 95%CI: 0.82-1.17).
There was a U-shaped association between baseline betaine levels and the risk of first ischemic stroke in hypertensive patients, with a turning point at about 77.7 μmol/L. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.
甜菜碱（一种微量营养素）具有重要的生物学功能（例如，防止细胞过早凋亡和作为甲基供体）。我们研究了基线血清甜菜碱与高血压患者首次中风发病风险之间的关系。
我们进行了一项巢式病例对照研究，纳入了 622 例首次中风（包括 502 例缺血性中风、118 例出血性中风和 2 例不确定类型的中风）患者和来自中国脑卒中一级预防试验（CSPPT）的 622 名匹配对照者。该研究于 2008 年 5 月至 2013 年 8 月进行。研究结局包括首次中风及其亚型：首次缺血性和出血性中风。
基线血清甜菜碱与首次缺血性中风风险之间存在 U 型关联。在甜菜碱<77.7μmol/L 的患者中，随着甜菜碱水平的升高（每增加 10μmol/L：OR，0.87；95%CI：0.77-0.99），首次缺血性中风的风险降低，而在甜菜碱≥77.7μmol/L 的患者中，随着甜菜碱的增加，首次缺血性中风的风险增加（OR，1.17；95%CI：1.01-1.36）。然而，血清甜菜碱与首次出血性中风的风险之间没有显著关联（每增加 10μmol/L：OR，0.98；95%CI：0.82-1.17）。
高血压患者基线甜菜碱水平与首次缺血性中风风险之间存在 U 型关联，转折点约为 77.7μmol/L。
